AirSculpt Technologies Inc (AIRS) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate Artivion’s ability to translate clinical innovation into profitable growth, positioning the company for accelerated market share gains in the aortic‑dissection and mechanical‑valve segments.

Key Takeaways

• Q4 revenue $118.3M, up 18.5% YoY
• Adjusted EBITDA $22.7M, margin 19.2%
• Stent graft sales +36% Q4, driven by AMDS
• On‑X revenue +24% Q4, new $100M U.S. opportunity
• 2026 guidance: 10‑14% revenue growth, EBITDA $105‑110M

Pulse Analysis

Artivion’s Q4 performance underscores the strategic payoff of expanding its minimally invasive aortic‑dissection platform, AMDS. By leveraging favorable reimbursement and early adoption in roughly 10% of target U.S. accounts, the company achieved a 36% jump in stent‑graft revenue, a rate that outpaces most peers in the cardiovascular device space. This momentum is reinforced by the pending FDA pre‑market approval (PMA) slated for mid‑2026, which should remove administrative barriers and accelerate volume growth across both domestic and international markets.

Beyond the flagship AMDS, Artivion’s mechanical heart‑valve line, On‑X, delivered a 24% revenue increase, buoyed by a newly quantified $100 million U.S. opportunity and robust clinical data that favor mechanical over bioprosthetic solutions for younger patients. The company’s disciplined expense management—evident in a 360‑basis‑point SG&A efficiency improvement—allowed EBITDA margins to expand by nearly 200 basis points year‑over‑year, delivering double‑digit profitability while still generating positive free cash flow despite a $20 million facility outlay.

Looking ahead, Artivion’s guidance for 2026 reflects confidence in its pipeline and market positioning. Projected revenue growth of 10‑14% and EBITDA of $105‑110 million hinge on the successful FDA clearance of AMDS, the anticipated NEXUS stent‑graft approval, and continued enrollment in the ARTISAN trial, which targets an $80 million U.S. opportunity by 2029. Coupled with planned capital investments to scale On‑X production and upgrade IT infrastructure, the firm is poised to capture incremental addressable market share while maintaining margin expansion, making it a compelling play for investors focused on high‑growth med‑tech innovators.